Last reviewed · How we verify
Mosunetuzumab (SC)
Mosunetuzumab is a bispecific antibody that simultaneously engages CD20 on B cells and CD3 on T cells to redirect T cell killing of B cell lymphomas.
Mosunetuzumab is a bispecific antibody that simultaneously engages CD20 on B cells and CD3 on T cells to redirect T cell killing of B cell lymphomas. Used for Relapsed or refractory B-cell non-Hodgkin lymphoma, Follicular lymphoma.
At a glance
| Generic name | Mosunetuzumab (SC) |
|---|---|
| Also known as | Mosunetuzumab, RO7030816 |
| Sponsor | The Lymphoma Academic Research Organisation |
| Drug class | Bispecific antibody (T-cell engager) |
| Target | CD20 and CD3 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
As a bispecific T-cell engager (BiTE), mosunetuzumab bridges cytotoxic T lymphocytes to CD20-expressing malignant B cells, bringing them into close proximity to facilitate T cell-mediated destruction of lymphoma cells. This dual-targeting approach leverages the patient's own immune system to eliminate tumor cells while potentially reducing systemic toxicity compared to traditional chemotherapy.
Approved indications
- Relapsed or refractory B-cell non-Hodgkin lymphoma
- Follicular lymphoma
Common side effects
- Cytokine release syndrome
- Infections
- Neutropenia
- Fatigue
- Pyrexia
Key clinical trials
- Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial (PHASE2)
- Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma (PHASE3)
- A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma (PHASE1)
- A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma (PHASE1, PHASE2)
- A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) (PHASE1)
- A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (PHASE3)
- A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (PHASE2)
- A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mosunetuzumab (SC) CI brief — competitive landscape report
- Mosunetuzumab (SC) updates RSS · CI watch RSS
- The Lymphoma Academic Research Organisation portfolio CI